Intratumoral Cell Neighborhoods Coordinate Outcomes in Pancreatic Ductal Adenocarcinoma

Authors: Wattenberg, Max M., Colby, Sarah, Garrido-Laguna, Ignacio, Xue, Yuqing, Chang, Renee, Delman, Devora, Lee, Jesse, Affolter, Kajsa, Mulvihill, Sean J., Beg, M. Shaalan, Wang-Gillam, Andrea, Wade, James Lloyd, III, Guthrie, Katherine A., Chiorean, E. Gabriela, Ahmad, Syed A., Lowy, Andrew M., Philip, Philip Agop, Sohal, Davendra P.S., Beatty, Gregory L.

Source: In Gastroenterology June 2024 166(6):1114-1129

Cabozantinib plus atezolizumab in previously untreated advanced hepatocellular carcinoma and previously treated gastric cancer and gastroesophageal junction adenocarcinoma: results from two expansion cohorts of a multicentre, open-label, phase 1b trial (COSMIC-021)

Authors: Li, Daneng, Loriot, Yohann, Burgoyne, Adam M., Cleary, James M., Santoro, Armando, Lin, Daniel, Aix, Santiago Ponce, Garrido-Laguna, Ignacio, Sudhagoni, Ramu, Guo, Xiang, Andrianova, Svetlana, Paulson, Scott

Source: In eClinicalMedicine January 2024 67

MOONRAY-01, a phase 1 study of LY3962673, a potent, orally bioavailable, and selective KRAS G12D inhibitor in KRAS G12D -mutant solid tumors.

Authors: Lakhani, Nehal J., Melisi, Davide, Subbiah, Vivek, Ammakkanavar, Natraj Reddy, O'Reilly, Eileen M., Cassier, Philippe Alexandre, Wainberg, Zev A., Duffy, Austin G., Patnaik, Amita, Fujiwara, Yutaka, Oberstein, Paul Eliezer, Garcia-Carbonero, Rocio, Wright, Jennifer, Lin, Aimee K., Li, Jian, Axelson, Michael D., Garrido-Laguna, Ignacio

Source: Journal of Clinical Oncology; 2025 Supplement 4, Vol. 43, pTPS845-TPS845, 47p

Cost-effectiveness of NALIRIFOX compared to other first-line treatments for metastatic pancreatic cancer.

Authors: Tan, Chia Jie, Liu, Haopeng, Farrokhi, Pegah, Garrido-Laguna, Ignacio, Stenehjem, David D.

Source: Journal of Clinical Oncology; 2025 Supplement 4, Vol. 43, p733-733, 121p

Safety, efficacy, and on-treatment circulating tumor DNA (ctDNA) changes from a phase 1 study of RMC-6236, a RAS(ON) multi-selective, tri-complex inhibitor, in patients with RAS mutant pancreatic ductal adenocarcinoma (PDAC).

Authors: Garrido-Laguna, Ignacio, Wolpin, Brian M., Park, Wungki, Azad, Nilofer Saba, Spira, Alexander I., Starodub, Alexander, Sommerhalder, David, Punekar, Salman Rafi, Herzberg, Benjamin, Barve, Minal A., Pelster, Meredith, Valerin, Jennifer Brooke, Hecht, Joel R, Vora, Rashmi, Hegde, Aparna Madhukeshwar, Gustafson, Clay, Tao, Lin, Kar, Sumit, Lin, Kevin K., Hong, David S.

Source: Journal of Clinical Oncology; 2025 Supplement 4, Vol. 43, p722-722, 121p

Disparities in prophylactic tetracycline use among patients with metastatic colorectal cancer undergoing treatment with EGFR inhibitors.

Authors: Rubnitz, Zach, Braun, Emma, Jridi, Amani, Florou, Vaia, Garrido-Laguna, Ignacio, Nevala-Plagemann, Christopher Duane

Source: Journal of Clinical Oncology; 2025 Supplement 4, Vol. 43, p109-109, 307p

Therapeutic Targeting of Autophagy in Pancreatic Cancer

Authors: Foth, Mona, Garrido-Laguna, Ignacio, Kinsey, Conan G.

Source: In Surgical Oncology Clinics of North America October 2021 30(4):709-718

Detection of circulating tumor DNA without a tumor-informed search using next-generation sequencing is a prognostic biomarker in pancreatic ductal adenocarcinoma

Authors: Affolter, Kajsa E., Hellwig, Sabine, Nix, David A., Bronner, Mary P., Thomas, Alun, Fuertes, Carrie L., Hamil, Cindy L., Garrido-Laguna, Ignacio, Scaife, Courtney L., Mulvihill, Sean J., Underhill, Hunter R.

Source: In Neoplasia September 2021 23(9):859-869

A Phase I, First‐in‐Human Study of GSK2849330, an Anti‐HER3 Monoclonal Antibody, in HER3‐Expressing Solid Tumors

Authors: Gan, Hui K., Millward, Michael, Jalving, Mathilde, Garrido‐Laguna, Ignacio, Lickliter, Jason D., Schellens, Jan H.M., Lolkema, Martijn P., Van Herpen, Carla L.M., Hug, Bruce, Tang, Lihua, O'Connor‐Semmes, Robin, Gagnon, Robert, Ellis, Catherine, Ganji, Gopinath, Matheny, Christopher, Drilon, Alexander

Source: Oncologist. 26(10):e1844-e1853

Availability: http://explore.bl.uk/primo_library/libweb/action/display.do?tabs=detailsTab&gathStatTab=true&ct=display&fn=search&doc=ETOCvdc_100131000552.0x000001&indx=1&recIds=ETOCvdc_100131000552.0x000001

Emerging Treatment Strategies in Pancreatic Cancer

Authors: Trunk, Andrew, Miotke, Laura, Nevala-Plagemann, Christopher, Verdaguer, Helena, Macarulla, Teresa, Garrido-Laguna, Ignacio

Source: Pancreas. 50(6):773-787

Availability: http://explore.bl.uk/primo_library/libweb/action/display.do?tabs=detailsTab&gathStatTab=true&ct=display&fn=search&doc=ETOCvdc_100182314311.0x000001&indx=1&recIds=ETOCvdc_100182314311.0x000001

Survival Outcomes Based on Sequence of Therapy Using FOLFIRINOX and Nab-Paclitaxel + Gemcitabine in Metastatic Pancreatic Ductal Adenocarcinoma

Authors: Baron, Margaret Kelsey, Wang, Xuechen, Nevala-Plagemann, Christopher, Moser, Justin C., Haaland, Benjamin, Garrido-Laguna, Ignacio

Source: Pancreas. 50(6):796-802

Availability: http://explore.bl.uk/primo_library/libweb/action/display.do?tabs=detailsTab&gathStatTab=true&ct=display&fn=search&doc=ETOCvdc_100182314333.0x000001&indx=1&recIds=ETOCvdc_100182314333.0x000001

Genomic Profiling of Rare Undifferentiated Sarcomatoid Subtypes of Pancreatic Carcinomas: In Search of Therapeutic Targets.

Authors: Faber, Erik B., Krause, Harris B., Amin, Khalid, Walker, Philip, Hosein, Peter J., Shields, Anthony F., Lenz, Heinz-Josef, Prakash, Ajay, Goel, Sanjay, Oberley, Matthew, Malleo, Giuseppe, Luchini, Claudio, Hwang, Justin, Florou, Vaia, Garrido‐Laguna, Ignacio, Lou, Emil

Source: JCO Precision Oncology; 12/1/2024, Vol. 8, p1-9, 9p

Subject Terms: IMMUNE checkpoint inhibitors, DNA analysis, IMMUNE checkpoint proteins, PANCREATIC duct, NUCLEOTIDE sequencing

Inhibition of MEK1/2 Forestalls the Onset of Acquired Resistance to Entrectinib in Multiple Models of NTRK1-Driven Cancer

Authors: Vaishnavi, Aria, Scherzer, Michael T., Kinsey, Conan G., Parkman, Gennie L., Truong, Amanda, Ghazi, Phaedra, Schuman, Sophia, Battistone, Benjamin, Garrido-Laguna, Ignacio, McMahon, Martin

Source: In Cell Reports 4 August 2020 32(5)

Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1–2 trials

Authors: Doebele, Robert C, Drilon, Alexander, Paz-Ares, Luis, Siena, Salvatore, Shaw, Alice T, Farago, Anna F, Blakely, Collin M, Seto, Takashi, Cho, Byung Chul, Tosi, Diego, Besse, Benjamin, Chawla, Sant P, Bazhenova, Lyudmila, Krauss, John C, Chae, Young Kwang, Barve, Minal, Garrido-Laguna, Ignacio, Liu, Stephen V, Conkling, Paul, John, Thomas, Fakih, Marwan, Sigal, Darren, Loong, Herbert H, Buchschacher, Gary L, Jr, Garrido, Pilar, Nieva, Jorge, Steuer, Conor, Overbeck, Tobias R, Bowles, Daniel W, Fox, Elizabeth, Riehl, Todd, Chow-Maneval, Edna, Simmons, Brian, Cui, Na, Johnson, Ann, Eng, Susan, Wilson, Timothy R, Demetri, George D ^*

Source: In The Lancet Oncology February 2020 21(2):271-282

Lymph Node Ratio in Pancreatic Adenocarcinoma After Preoperative Chemotherapy vs. Preoperative Chemoradiation and Its Utility in Decisions About Postoperative Chemotherapy

Authors: Swords, Douglas S., Francis, Samual R., Lloyd, Shane, Garrido-Laguna, Ignacio, Mulvihill, Sean J., Gruhl, Joshua D., Christensen, Miles C., Stoddard, Gregory J., Firpo, Matthew A., Scaife, Courtney L.

Source: In Journal of Gastrointestinal Surgery July 2019 23(7):1401-1413

The impact of squamous cell carcinoma histology on outcomes in nonmetastatic pancreatic cancer

Authors: Gruhl, Joshua D., Garrido‐Laguna, Ignacio, Francis, Samual R., Affolter, Kajsa, Tao, Randa, Lloyd, Shane

Source: Cancer medicine. 9(5):1703-1711

Availability: http://explore.bl.uk/primo_library/libweb/action/display.do?tabs=detailsTab&gathStatTab=true&ct=display&fn=search&doc=ETOCvdc_100103068446.0x000001&indx=1&recIds=ETOCvdc_100103068446.0x000001

Refusal of Local Therapy in Esophageal Cancer and Impact on Overall Survival

Authors: Parsons, Matthew, Lloyd, Shane, Johnson, Skyler, Scaife, Courtney, Varghese, Thomas, Glasgow, Robert, Garrido-Laguna, Ignacio, Tao, Randa

Source: Annals of surgical oncology. 28(2):663-675

Availability: http://explore.bl.uk/primo_library/libweb/action/display.do?tabs=detailsTab&gathStatTab=true&ct=display&fn=search&doc=ETOCvdc_100191445342.0x000001&indx=1&recIds=ETOCvdc_100191445342.0x000001

A phase 1 study of the CD40 agonist MEDI5083 in combination with durvalumab in patients with advanced solid tumors.

Authors: Tran, Ben, Voskoboynik, Mark, Bendell, Johanna, Gutierrez, Martin, Lemech, Charlotte, Day, Daphne, Frentzas, Sophia, Garrido-Laguna, Ignacio, Standifer, Nathan, Wang, Fujun, Ferte, Charles, Wang, Yue, Das, Mayukh, Carneiro, Benedito A

Source: Immunotherapy (1750743X); 2024, Vol. 16 Issue 11, p759-774, 16p

Survival of patients with metastatic HER2 positive gastro-oesophageal cancer treated with second-line chemotherapy plus trastuzumab or ramucirumab after progression on front-line chemotherapy plus trastuzumab

Authors: Nevala-Plagemann, Christopher, Moser, Justin, Gilcrease, Glynn Weldon, Garrido-Laguna, Ignacio

Source: In ESMO Open 2019 4(4)

Immune Checkpoint Inhibitors in Combinations for Hepatocellular Carcinoma

Authors: Kalasekar, Sharanya Maanasi, Garrido‐Laguna, Ignacio, Evason, Kimberley Jane, Corey, Kathleen E., Malhi, Harmeet

Source: Hepatology. 73(6):2591-2593

Availability: http://explore.bl.uk/primo_library/libweb/action/display.do?tabs=detailsTab&gathStatTab=true&ct=display&fn=search&doc=ETOCvdc_100122702324.0x000001&indx=1&recIds=ETOCvdc_100122702324.0x000001